IRVING, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. announced results from a first-in-man study of RTA 402 in patients with advanced cancers, presented in an oral session at the annual meeting of the American Society for Clinical Oncology. RTA 402 is the clinical lead from Reata’s Antioxidant Inflammation Modulators (AIMs), a new and highly promising category of drugs for the treatment of cancer and inflammation. One of the study’s Principal Investigators, Dr. David Hong from the University of Texas M. D. Anderson Cancer Center, presented data showing that RTA 402 had an excellent safety profile and provided a clinical benefit in a significant percentage of patients. Investigators also confirmed that the drug was active against its biological targets, NF-kappa B and STAT3. These pro-inflammatory transcription factors promote tumor growth, angiogenesis, invasion, metastasis, and resistance to therapy. Overall, RTA 402 showed a profile of disease control and tumor reduction comparable or superior to any recently approved targeted therapy in a Phase I patient population and a markedly superior side effect profile.
